Get tested for Alzheimer’s disease with Duritect-AD™
If you suspect that you or someone you care for may have Alzheimer’s disease, a Duritect™ blood test could help you and your doctor arrive at a
diagnosis earlier.1
Why get tested
with Duritect-AD™?
Nearly 7 million people in the U.S. are affected by Alzheimer’s disease (AD), which has significant practical, emotional, and financial impacts on people who live with it.2
Duritect-AD™ is a simple blood test to quickly and reliably assess your risk of having Alzheimer’s disease – helping you get on the path to a confirmed diagnosis sooner.1
Earlier diagnosis could enable earlier intervention and treatment to improve your long-term outcomes and quality of life.3-5 It also provides more time for the necessary preparations you might need to make for the future.4-6
Learn more on this page
- Features and benefits
- Step-by-step guide
- Start your journey to a diagnosis
About the test
Duritect-AD™ is a disease "risk assessment" test. It combines a simple blood test with machine learning analysis to assess your risk of having Alzheimer’s disease.1,7
Your doctor can recommend Duritect-AD™ for you if appropriate. It is intended to be used as an aid in the diagnostic evaluation of adult patients aged 55+ who show signs or symptoms of cognitive impairment that could indicate Alzheimer’s disease or other causes of cognitive decline.1
The test looks for the presence of specific autoantibodies in your blood as biomarkers of the disease.1
Features and benefits
Highly Accurate
Convenient
Simple
Minimally invasive
Rapid
Affordable
Step-by-step guide
Here’s what to expect when you get tested with Duritect-AD™:
Here’s how to get tested with Duritect-AD™:
- Step 1: Make an appointment with your doctor.
- Step 2: Your doctor will assess your situation and determine whether Duritect-AD™ is appropriate for you.
- Step 3: Once the test is ordered, you can make the payment and provide a blood sample at your healthcare provider.
Your blood sample will be sent to Durin Life Sciences’ laboratory and analyzed using a combination of scientific approaches.
The test results are generally available 48–72 hours after the laboratory receives your blood sample.*
* Delays in the delivery of samples to the laboratory may impact the turnaround time for results.
Your doctor will discuss the results with you to explain what they mean and recommend the best course of action.
Your results will show either an increased risk or a typical risk of Alzheimer’s disease.3
- Increased risk: Your Alzheimer's disease risk score indicates that you have a higher probability of having Alzheimer’s disease pathology.
- Typical risk: Your Alzheimer's disease risk score indicates that you have a typical probability of having Alzheimer’s disease pathology.
Whether you have an increased risk or a typical risk, your doctor will help determine what your next steps should be.
You may be sent for more tests to confirm the diagnosis or to rule out other causes of your symptoms.
Start your journey
to a diagnosis
If your doctor has recommended Duritect-AD™, taking the test is a proactive step toward understanding your health and receiving the right care.
Getting reliable information about the possibility of having Alzheimer’s disease will empower you and your doctor to manage your health and make timely decisions.
All you have to do to move forward is pay for the test and have a blood sample taken. Act now to pursue a diagnosis as soon as possible.
CSO, Durin Life Sciences
Abbreviations and references
*Delays in the delivery of samples to the laboratory may impact the turnaround time for results.
References
- [Duritect-AD™. Indications for use. Durin Life Sciences. 2024.]
- Alzheimer’s Association. 2024 Alzheimer’s disease facts and figures. [Online] 2024 [Cited 2024 Jul 30]. Available from: www.alz.org/alzheimers-dementia/facts-figures.
- DeMarshall CA, Viviano J, Emrani S, et al. Early detection of Alzheimer’s disease-related pathology using a multi-disease diagnostic platform employing autoantibodies as blood-based biomarkers. J Alzheimer’s Dis. 2023;92:1077–1091.
- Rasmussen J, Langerman H. Alzheimer’s disease – why we need early diagnosis. Degen Neurol Neuromusc Dis. 2019;9:123–130.
- Nasreddine Z, Garibotto V, Kyaga S, Padovani A. The early diagnosis of Alzheimer's disease: a patient-centred conversation with the care team. Neurol Ther. 2023;12:11–23.
- Gaster B, Pope TM. Guiding the future: rethinking the role of advance directives in the care of people with dementia. Hastings Cent Rep. 2024:54 (Suppl 1):S33-S39. doi: 10.1002/hast.1553.
- Duritect™’s analytical and clinical validation data, company internal, 2025.